Q32 Bio Shares Soar After Alopecia Drug Bempikibart Meets Phase 2 Goal

Shares of Q32 Bio Inc. (NASDAQ:QTTB) surged as much as 60% on Monday after the clinical-stage biotechnology company announced positive topline results from a Phase 2a trial of its drug candidate, bempikibart, for treating severe alopecia areata.

Trial Results in Detail

Q32 Bio reported that the SIGNAL-AA study met its primary endpoint, demonstrating a statistically significant improvement in hair regrowth. The trial evaluated bempikibart in 33 patients with severe or very severe alopecia areata, an autoimmune disorder that causes hair loss.

Key findings from the 36-week trial include:

• A mean percent reduction in the Severity of Alopecia Tool (SALT) score from baseline of 35.3% in the prespecified modified intent-to-treat (mITT) analysis.
• A SALT-20 response (at least a 20% improvement in SALT score) was achieved by 40.0% of patients in the mITT analysis.
• In the intent-to-treat analysis of all enrolled patients, 30.3% achieved a SALT-20 response.

The company noted that 36.4% of patients in the study had previously been treated with oral JAK inhibitors, a common class of drugs for the condition, indicating bempikibart's potential in a treatment-experienced population.

Ad

Safety Profile and Next Steps

According to the company's release, bempikibart demonstrated a generally well-tolerated safety profile. There were no serious adverse events or severe (Grade 3 or higher) adverse events related to the treatment. The most frequently reported side effect was a mild injection site reaction, observed in 36.3% of participants, which typically resolved without intervention.

Based on these results, Q32 Bio stated its intention to advance bempikibart into a registration-directed program, with plans to initiate it in the first half of 2027. The company also plans to present the full results from the study at a future medical conference.

Market Context

The strong positive data provides a significant catalyst for Q32 Bio, as alopecia areata represents a market with a substantial unmet medical need. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking specific signaling pathways (IL-7 and TSLP). The positive safety and efficacy data from this mid-stage trial are a crucial step toward potential regulatory approval and commercialization.